Biotrial Says It 'Rigorously Complied' With Standards In French Phase I Study

This article was originally published in SRA

08 Feb 2016
News

Ian Schofield @ScripIanS ian.schofield@informa.com

Executive Summary

Biotrial, the French CRO that conducted the Phase I study of Bial's FAAH inhibitor BIA 10-2474, has taken issue with a government inspection report that questioned its decision to continue dosing of the drug after one of the volunteers was taken to hospital, saying that it applied the precautionary principle and "rigorously complied" with international clinical trial standards¹^,2.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS118538

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS118538

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Biotrial Says It 'Rigorously Complied' With Standards In French Phase I Study

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert